Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 20mg | $230.00$130.00 | $6.50/mg | In stock | Jul 7 |
| vial | 50mg | $450.00$290.00 | $5.80/mg | In stock | Jul 7 |
| vial | 100mg | $630.00$490.00 | $4.90/mg | In stock | Jul 7 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| TB202605 | — | 99.8% | TrustPointe Analytics | Endotoxin, Heavy metals | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. TB-500 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Peptide Partners sell TB-500?
Yes — Peptide Partners currently lists TB-500 in 3 variants starting at $490.00 ($4.90/mg).
Is Peptide Partners's TB-500 third-party tested?
Yes — Disclosed Labs has indexed 4 Certificates of Analysis for Peptide Partners's TB-500, with the most recent showing 99.8% purity. Peptide Partners holds an overall trust grade of A (91/100) across all 106 COAs on file.
What is Peptide Partners's trust grade for TB-500?
Peptide Partners has an overall Disclosed Labs trust grade of A (91/100), computed from 106 COAs across all peptides. The most recent TB-500 COA was issued by TrustPointe Analytics.
Where is the cheapest TB-500?
As of the latest data, Peptide Supply Co. offers TB-500 at $3.40/mg — compare with Peptide Partners's listing at $4.90/mg. See the full TB-500 price comparison.
Is TB-500 legal to buy?
TB-500 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| TB202601 | — | 99.9% | TrustPointe Analytics | Endotoxin, Heavy metals | Confirmed | View |
| TB20251012 | — | — | TrustPointe Analytics | Heavy metals | Confirmed | View |
| TB20250614 | — | 99.7% | TrustPointe Analytics | Endotoxin | Confirmed | View |